ACR 2022
How Does Risk for CV Events Differ Between Tofacitinib and TNFi in RA?
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
Your search for tofacitinib returned 16 results
DDW 2022
Tofacitinib, Vedolizumab Effective for UC Post-Anti-TNF Agent Failure
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
News
CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
ACG 2022
Insurance Companies Have Poor Adherence to Guidelines for UC, CD
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
News
Drug Repurposing Study Shows PDE5 Inhibitors Do Not Reduce Dementia Risk
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
News
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
News
WHO Living Guideline Updated for Drug Treatment of COVID-19
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19
